Terkko Navigator / Lancet Oncology

Sarcopenia and adiposity linked to overall survival

A CRITICal period for chemoradiotherapy in gastric cancer

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Targeting EZH2 with tazemetostat

Lawsuit filed against FDA for not reviewing e-cigarettes

Short vs long course adjuvant chemotherapy for colon cancer

Oncologists burnout in the spotlight

Health care for cancer survivors in the USA

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Combining top-ranked immunotherapeutics in lung cancer

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

New interventions offer prostate cancer hope

Aiming for complete responses in renal-cell carcinoma

Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts?

Adjuvant aromatase inhibition: more options for patients

Can umbralisib bring PI3Kδ out of the shadows?

Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?

The brim of uncertainty in adjuvant treatment of melanoma

ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?

Vulvar field resection: innovative procedure or same old?

Predicting early relapse in follicular lymphoma: have we turned a corner?

Adjuvant therapy in colon cancer: less is more

The NHS and migrant patients with cancer

Guidelines for sub-Saharan Africa: a call for evidence

Genetic testing for young women with breast cancer

Genetic testing for young women with breast cancer– Authors' reply

Correction to Lancet Oncol 2013; 14: 1067–76

Correction to Lancet Oncol 2017; 18: 1221–37

Correction to Lancet Oncol 2018; 19: 295–309

Correction to Lancet Oncol 2018; 19: 434–36

Correction to Lancet Oncol 2018; 19: 474–85

Correction to Lancet Oncol 2018; 19: 510–20

Possible X chromosome-linked transmission of ovarian cancer

Ultra-processed foods might increase cancer risk

Larotrectinib in TRK fusion-positive cancers

Dasatinib in paediatric chronic myeloid leukaemias

Colorectal adenoma risk in childhood cancer survivors

EMA guidance on radium-223 dichloride in prostate cancer

Slogans and donor pages of cancer centres: do they convey discordant messages?

Opportunities for improving oncology care

The rise and fall of the wellness warriors

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study